15th Apr 2011 11:45
Press Release | 15 April 2011 |
LIDCO GROUP PLC
("LiDCO" or the "Company")
NOTIFICATION OF MAJOR INTEREST IN SHARES
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | ||||
1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Lidco Group PLC | |||
2 Reason for the notification (please tick the appropriate box or boxes): | ||||
An acquisition or disposal of voting rights | YES | |||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | NO | |||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | NO | |||
An event changing the breakdown of voting rights | NO | |||
Other (please specify): | NO | |||
3. Full name of person(s) subject to thenotification obligation: iii | Ingalls & Snyder LLC ("I&S") and Ingalls & Snyder Value Partners LP ("ISVP"). | |||
4. Full name of shareholder(s) (if different from 3.):iv | I&S, on behalf of its clients, has dispositive authority over (i.e. the power and authorization to sell at I&S's discretion) 24,424,368 shares. In respect of 13,820,000 of such 24,424,368 shares ISVP (as beneficial owner) shares dispositive authority with I&S and has voting authority. So in respect of the 13,820,000 shares beneficially held by ISVP, I&S has and ISVP share dispositive authority and ISVP has voting authority. | |||
5. Date of the transaction and date onwhich the threshold is crossed orreached: v | April 13, 2011 | |||
6. Date on which issuer notified: | April 14, 2011 | |||
7. Threshold(s) that is/are crossed orreached: vi, vii | Interest in excess of 14% of issued share capital. | |||
8. Notified details: | ||||||||||||||||
A: Voting rights attached to shares viii, ix | ||||||||||||||||
Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | ||||||||||||||
NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | ||||||||||||
Direct | Direct xi | Indirect xii | Direct | Indirect | ||||||||||||
Ordinary Shares of 0.5 pence ISIN GB0030546849 | 23,855,746 | - | 24,424,368 | See note 4 above. I&S has dispositive authority over 24,424,368 shares and ISVP has voting authority and shares dispositive authority in respect of 13,820,000 of such shares. | - | 14.04% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights). | - | |||||||||
B: Qualifying Financial Instruments | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | ||||||||||||
N/A | ||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||||||||||||
Resulting situation after the triggering transaction | ||||||||||||||||
Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to
| % of voting rights xix, xx
| |||||||||||
N/A | Nominal | Delta | ||||||||||||||
Total (A+B+C) | ||||||||||||||||
Number of voting rights | Percentage of voting rights | |||||||||||||||
24,424,368 (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights). | 14.04% (Note: For these purposes we have assumed that dispositive authority is equivalent to voting rights). | |||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
N/A | ||
Proxy Voting: | ||
10. Name of the proxy holder: | N/A | |
11. Number of voting rights proxy holder will ceaseto hold: | N/A | |
12. Date on which proxy holder will cease to holdvoting rights: | N/A | |
13. Additional information: | ||
14. Contact name: | Frank Stolba | |
15. Contact telephone number: | (001) (212) 269 - 7814 | |
- Ends -
For further information, please contact:
LiDCO Group Plc | |
Terry O'Brien (CEO) | Tel: +44 (0)20 7749 1500 |
Paul Clifford (Finance Director) | |
Theresa Wallis (Chairman) | www.lidco.com |
FinnCap | |
Geoff Nash / Henrik Persson Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
Abchurch | |
Adam Michael / Joanne Shears / Simone Elviss / Claire Dickinson | Tel: +44 (0) 20 7398 7728 |
www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the measurement, analysis, audit, training and sharing of real-time and historic hemodynamic data, in both critical care units and the operating theatre.
Scientific evidence is increasingly linking the optimisation of patients' hemodynamic status with better outcomes and reduced hospital stays and LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
Key Products:
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) | |
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: | |
·; | early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
·; | quantification of hemodynamic response, |
·; | guidance on effective delivery of fluids to ensure the right amount at the right time |
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. |
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
Clinical Validation & Education
LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimising cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimisation study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.
LiDCO Distribution Network:
LiDCO products are sold through Covidien's sales force in the US. LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.
Related Shares:
LID.L